Konstantin Zakashansky, MD, discusses data with olaparib in advanced, recurrent, platinum-sensitive, BRCA-mutated ovarian cancer.
Konstantin Zakashansky, MD, a gynecologic oncologist and an associate professor of Obstetrics, Gynecology, and Reproductive Science with Mount Sinai, discusses data with olaparib (Lynparza) in advanced, recurrent, platinum-sensitive, BRCA-mutated ovarian cancer.
As the largest similar study to the phase 3 SOLO2 trial, Study 19 similarly showed that olaparib yielded improvements in progression-free survival (PFS) and overall survival (OS) in patients with recurrent ovarian, fallopian, and peritoneal cancer. The study featured patients who were platinum sensitive and had received 2 previous lines of therapy, says Zakashansky. Notably, Study 19 compared the use of olaparib capsules rather than olaparib tablets, which were used in SOLO2.
Preliminary data from SOLO2 showed improvements in PFS with olaparib, although at the time, OS data were not available. During the 2020 ASCO Virtual Scientific Program, follow-up data from the SOLO-2 trial were presented and showed an improvement in PFS, which led to the FDA approval of olaparib in December 2018. The approval was due to the significant improvement of survival observed within this subset of patients with recurrent, BRCA-mutated, and platinum sensitive ovarian, concludes Zakashansky.